Astodrimer - Starpharma
Alternative Names: 3% w/w SPL7013 Gel; Astodrimer sodium; Betadine BV; BETADINE BV Gel; Betafem BV; BRI-7013; Fleurstat BVgel; SPL-7013; VIRALEZE; Viraleze; VivaGel; VivaGel®BVLatest Information Update: 28 Feb 2024
At a glance
- Originator Biomolecular Research Institute
- Developer Aspen Pharmacare; Starpharma; The Scripps Research Institute
- Class Antibacterials; Antivirals; Dendrimers; Peptides
- Mechanism of Action Anion transport protein modulators; Surface antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Bacterial vaginosis; COVID 2019 infections
- Phase I/II Herpes simplex virus infections; HIV infections
- Preclinical Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Middle East respiratory syndrome coronavirus; Respiratory syncytial virus infections; Severe acute respiratory syndrome
- No development reported Conjunctivitis; Human papillomavirus infections; Zika virus infection
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention, In volunteers) in Australia (Intranasal, Spray)
- 12 Jun 2023 Starpharma plans to launch astodrimer for Covid-2019 infection in Malaysia
- 05 Jun 2023 Registered for COVID-2019 infections in Malaysia (Intranasal)